Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence
- 29 March 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 39 (7), 627-645
- https://doi.org/10.1007/s40264-016-0416-y
Abstract
Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions. Appropriate treatment will be based on the unique risk–benefit profile in each case.This publication has 146 references indexed in Scilit:
- Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol DependenceNeuropsychopharmacology, 2011
- Effect of Acamprosate on Magnetic Resonance Spectroscopy Measures of Central Glutamate in Detoxified Alcohol-Dependent IndividualsArchives of General Psychiatry, 2010
- Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependenceAddictive Behaviors, 2009
- A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependenceDrug and Alcohol Dependence, 2009
- Gender Differences in Predictors of Treatment Attrition with High Dose Naltrexone in Cocaine and Alcohol DependenceThe American Journal on Addictions, 2008
- Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependenceJournal of Substance Abuse Treatment, 2008
- A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependenceAddictive Behaviors, 2008
- Effect of Naltrexone and Ondansetron on Alcohol Cue–Induced Activation of the Ventral Striatum in Alcohol-Dependent PeopleArchives of General Psychiatry, 2008
- Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and DisulfiramSchizophrenia Bulletin, 2005